Exelixis, INC. (EXEL) SEC Filings — 2024
15 SEC filings for Exelixis, INC. (EXEL) in 2024.
Filings
- Exelixis Files 10-Q for Q3 2024 — 10-Q · Oct 29, 2024
- Exelixis, Inc. Files 8-K for Undisclosed Event — 8-K · Oct 15, 2024
- Exelixis Files 10-Q for Q2 2024 — 10-Q · Aug 6, 2024
- Exelixis Adds Two Directors to Board — 8-K · Jun 3, 2024
- Exelixis, Inc. Files 8-K Report — 8-K · May 20, 2024
- Exelixis Acquires Kairos Therapeutics for $400M Upfront — 8-K · May 10, 2024
- Farallon Capital Updates Exelixis Stake — SC 13D/A · May 8, 2024
- Exelixis, Inc. Files 10-Q for Period Ending March 29, 2024 — 10-Q · Apr 30, 2024
- EXELIXIS, INC. DEF 14A Filing — DEF 14A · Apr 18, 2024
- Exelixis Appoints New Chief Medical and Scientific Officers — 8-K · Mar 29, 2024
- Vanguard Holds 18.9% Stake in Exelixis, 60.3M Shares — SC 13G/A · Feb 13, 2024
- Renaissance Technologies Discloses 3.4% Passive Stake in Exelixis — SC 13G · Feb 13, 2024
- EXELIXIS, INC. Files 2023 Annual Report on Form 10-K — 10-K · Feb 6, 2024
- BlackRock Amends Exelixis Stake, Files 17th SC 13G/A — SC 13G/A · Jan 24, 2024
- EXELIXIS 8-K: Financial Condition, Officer Comp, Exit Activities — 8-K · Jan 8, 2024